- The Wall Street Journal•11 hours ago
GlaxoSmithKline is pinning the future of its HIV business on an audacious bet: upending the decades-old triple-drug treatment strategy that has turned a fatal illness into a chronic condition.
- Motley Fool•yesterday
George Soros' namesake fund dumped its entire holdings in the iShares Nasdaq Biotechnology Index Fund, Gilead Sciences, and Novavax.
- Benzinga•2 days ago
Biotech is one of the sectors where M&A activities never stop, as the potential for growth and development is immense. After the termination of a $160 billion merger with Allergan plc Ordinary Shares (NYSE: ...
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||78.04 x 300|
|Ask||78.05 x 700|
|Day's Range||77.84 - 79.70|
|52wk Range||77.84 - 113.31|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||6.83|
|Avg Vol (3m)||10,159,655|
|Dividend & Yield||1.88 (2.36%)|